Immune Regulation of the Liver Through the PCSK9/CD36 Pathway During Heart Transplant Rejection
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
BACKGROUND: PCSK9 (proprotein convertase subtilisin/kexin 9), which is mainly secreted by the liver, is not only a therapeutic target for hyperlipidemia and cardiovascular disease, but also has been implicated in the immune regulation of infections and tumors. However, the role of PCSK9 and the liver in heart transplant rejection (HTR) and the underlying mechanisms remain unclear. METHODS: We assessed serum PCSK9 expression in both murine and human recipients during HTR and investigated the effect of PCSK9 ablation on HTR by using global knockout mice and a neutralizing antibody. Moreover, we performed multiorgan histological and transcriptome analyses, and multiomics and single-cell RNA-sequencing studies of the liver during HTR, as well. We further used hepatocyte-specific Pcsk9 knockout mice to investigate whether the liver regulated HTR through PCSK9. Last, we explored the regulatory effect of the PCSK9/CD36 pathway on the phenotype and function of macrophages in vitro and in vivo. RESULTS: Here, we report that murine and human recipients have high serum PCSK9 levels during HTR. PCSK9 ablation prolonged cardiac allograft survival and attenuated the infiltration of inflammatory cells in the graft and the expansion of alloreactive T cells in the spleen. Next, we demonstrated that PCSK9 was mainly produced and significantly upregulated in the recipient liver, which also showed a series of signaling changes, including changes in the TNF-α (tumor necrosis factor α) and IFN-γ (interferon γ) signaling pathways and the bile acid and fatty acid metabolism pathways. We found mechanistically that TNF-α and IFN-γ synergistically promoted PCSK9 expression in hepatocytes through the transcription factor SREBP2 (sterol regulatory element binding protein 2). Moreover, in vitro and in vivo studies indicated that PCSK9 inhibited CD36 expression and fatty acid uptake by macrophages and strengthened the proinflammatory phenotype, which facilitated their ability to promote proliferation and IFN-γ production by donor-reactive T cells. Last, we found that the protective effect of PCSK9 ablation against HTR is dependent on the CD36 pathway in the recipient. CONCLUSIONS: This study reveals a novel mechanism for immune regulation by the liver through the PCSK9/CD36 pathway during HTR, which influences the phenotype and function of macrophages and suggests that the modulation of this pathway may be a potential therapeutic target to prevent HTR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
Abifadel, M., Varret, M., Rabès, J.-P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., et al. (2003) · Nature Genetics · doi:10.1038/ng1161 · Cited by 2,985
Diversity, Mechanisms, and Significance of Macrophage Plasticity
Locati, M., Curtale, G., & Mantovani, A. (2020) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-012418-012718 · Cited by 2,199
Bonnardel, J., T’Jonck, W., Gaublomme, D., Browaeys, R., Scott, C. L., Martens, L., Vanneste, B., De Prijck, S., Nedospasov, S. A., Kremer, A., et al. (2019) · Immunity · doi:10.1016/j.immuni.2019.08.017 · Cited by 631
Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer
Liu, X., Bao, X., Hu, M., Chang, H., Jiao, M., Cheng, J., Xie, L., Huang, Q., Li, F., & Li, C.-Y. (2020) · Nature · doi:10.1038/s41586-020-2911-7 · Cited by 490
The Multifaceted Biology of PCSK9
Seidah, N. G., & Prat, A. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab035 · Cited by 232
Inhibiting PCSK9 — biology beyond LDL control
Stoekenbroek, R. M., Lambert, G., Cariou, B., & Hovingh, G. K. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0110-5 · Cited by 141
Defects in a liver-bone axis contribute to hepatic osteodystrophy disease progression
Lu, K., Shi, T.-S., Shen, S.-Y., Shi, Y., Gao, H.-L., Wu, J., Lu, X., Gao, X., Ju, H.-X., Wang, W., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.02.006 · Cited by 126
Apaijai, N., Moisescu, D. M., Palee, S., McSweeney, C. M., Saiyasit, N., Maneechote, C., Boonnag, C., Chattipakorn, N., & Chattipakorn, S. C. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.118.010838 · Cited by 90
Lipid-Modifying Agents, From Statins to PCSK9 Inhibitors
Preiss, D., Tobert, J. A., Hovingh, G. K., & Reith, C. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.11.072 · Cited by 75
Cited by
Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): From bench to bedside
Bao, X., Liang, Y., Chang, H., Cai, T., Feng, B., Gordon, K., Zhu, Y., Shi, H., He, Y., & Xie, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01690-3 · Cited by 187
Piezo1 specific deletion in macrophage protects the progression of liver fibrosis in mice
Luo, S., Zhao, X., Jiang, J., Deng, B., Liu, S., Xu, H., Tan, Q., Chen, Y., Zhang, Z., Pan, X., et al. (2023) · Theranostics · doi:10.7150/thno.86103 · Cited by 76
“As antigen processing cells, macrophages regulate the T cell function [38, 39].”
Self-citationAVCAPIR: A Novel Procalcific PIWI-Interacting RNA in Calcific Aortic Valve Disease
Han, D., Zhou, T., Li, L., Ma, Y., Chen, S., Yang, C., Ma, N., Song, M., Zhang, S., Wu, J., et al. (2024) · Circulation · doi:10.1161/circulationaha.123.065213 · Cited by 38
Self-citationGence, L., Morello, E., Rastegar, S., Apalama, M. L., Meilhac, O., Bascands, J., & Diotel, N. (2025) · European Journal of Neuroscience · doi:10.1111/ejn.16586 · Cited by 5
Wang, J. D. J., Teo, A. Y. T., Xiao, B., Chao, Y., Zhou, Z. D., Tan, B. J.-W., Chan, L.-L., Rosalie, E., & Tan, E.-K. (2026) · Translational Neurodegeneration · doi:10.1186/s40035-026-00568-y
Metadata
- Authors
- Zhang, X., Xu, H., Yu, J., Cui, J., Chen, Z., Li, Y., Niu, Y., Wang, S., Ran, S., Zou, Y., Wu, J., & Xia, J.
- Venue
- Circulation
- Published
- 2023-07-25
- Volume
- 148
- Issue
- 4
- Pages
- 336-353
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W4378348216
- Cited by
- 45
- References
- 9
- FWCI
- 10.73
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.